Recombinant mAbs tend to be unstable and susceptible to modification/degradation. These mAbs need to be identified/monitored for successful drug development. New advanced LC–MS workflows have been developed to meet such needs.

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Advanced Analytical Workflow Solutions for Monitoring Critical Quality Attributes of Monoclonal Antibodies

Newsletter